Artivion, Inc. (CYL.F)

19,12 +0,24 (+1,27%) Börsenschluss: 08:06AM CEST

Artivion, Inc.

1655 Roberts Boulevard N.W.
Kennesaw, GA 30144
United States
770 419 3355
https://artivion.com

Sektor(en): Healthcare
Branche: Medical Devices
Vollzeitmitarbeiter: 1.500

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. James Patrick Mackin	Chairman, President & CEO	2,21M	181,38k	1967
Ms. Amy D. Horton CPA	VP & Chief Accounting Officer	579,02k	110,16k	1970
Ms. Jean F. Holloway Esq.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	784,21k	N/A	1957
Mr. John E. Davis	Senior VP & Chief Commercial Officer	747,48k	25,67k	1965
Mr. Matthew A. Getz	VP of Human Resources & Chief Human Resources Officer	N/A	N/A	1969
Dr. Marshall S. Stanton M.D.	Senior VP of Clinical Research & Chief Medical Officer	573,69k	N/A	1957
Dr. Robert C. Thomson	Vice President of Research & Development	N/A	N/A	1970
Mr. Florian Tyrs	Vice President of Global Operations	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Corporate Governance

Artivion, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 3. Die grundlegenden Scores sind Audit: 3, Vorstand: 4, Shareholderrechte: 4, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.